Ikeoka 2007.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 90 adults and elderly (macrolide n = 42, placebo n = 40, excluded n = 8) Age in years (mean ± SD): macrolide: 62 ± 10, placebo: 59 ± 9 Setting: secondary care
Interventions	Indication: stable coronary disease Type of macrolide: azithromycin Route: per oral Dose: 500 mg x 1 for 3 days in week 1, followed by 500 mg x 1 weekly for 12 weeks, then 500 mg x 1 for 3 days in week 14 Duration of treatment: 14 weeks Total treatment dose: 9000 mg
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: unclear Adverse events ascertainment: participants asked + clinical examination Adverse events: data reported Antimicrobial resistance: not reported Death: data reported
Funding sources	None stated. Authors acknowledge supplying company (Pfizer).
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated, block randomisation
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo used.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants and clinicians blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low dropout, similar across groups
Selective reporting (reporting bias)	Low risk	Adverse events not stated clearly as an outcome. However, standardised ascertainment and adverse events reported.
Other bias	Low risk	None were identified.